therapy is an effective salvage treatment for heavily pretreated relapsed/refractory multiple myeloma. Haematologica. 2013; 98:xxx doi:10.3324/haematol.2013 in the outpatient setting and secondary admissions due to regimen toxicity occurred in 37/186 (20%). Treatment related mortality was evident in 2/186 (1%). In conclusion metronomic therapy is an effective late salvage treatment in relapsed/refractory Multiple Myeloma, with a high overall response rate and a favorable toxicity profile.
INTRODUCTION
Since the introduction of novel agents, especially in the context of autologous transplantation, overall survival (OS) and progression free survival (PFS) in MM have been extended to more than 7 and 4 year, respectively (1) . It is now recognized that the dominant adverse features for outcome relate to MM genetics, captured by metaphase cytogenetic abnormalities (2) , Fluorescence In Situ Hybridization (FISH)-derived amp1q21 (3) and del17p (4) and more recently gene expression profiling (GEP)-derived high risk (5) . While present in a minority of newly diagnosed MM patients, these grave prognostic markers increase with disease progression. Additional challenges arise towards the end stage of MM when many patients further present with cytopenia due either to extensive bone marrow involvement, exhausted hematopoiesis or, myelodysplastic syndrome (MDS).
Applied with anti-angiogenic therapeutic intent, thalidomide proved a major breakthrough in the treatment of relapsed/refractory MM (6) and MM in general (7, 8) .
Based on the concept that low-dose continuous application of certain cytotoxic drugs (e.g., doxorubicin, cis-platinum, cyclophosphamide) can inhibit tumor progression by interrupting neo-angiogenesis without increasing toxicity in experimental models and clinical practice (9-12), we developed a treatment schema of metronomically scheduled drug therapy, especially in the setting of pancytopenia, for relapsed/refractory MM (13) .
We are now updating our experience in 186 patients treated with metronomic therapy between March 2004 and January 2012, with a median follow-up period of 26 months.
METHODS

Patients
One-hundred-eighty-six (186) 
Metronomic Therapy
While variations in dosing occurred, the main elements of metronomic therapy consisted of bortezomib: 1.0 mg/m 2 
Statistical Analysis
Response and toxicity were assessed in 186 patients in accordance with the intent-to-treat principle. Response criteria used were the latest of the International Myeloma Working Group (IMWG) (14) . Toxicity was estimated using the National Cancer Institute Common Toxicity Criteria version 3.0 (15).
Overall survival (OS) and progression-free survival (PFS) were measured from the time of initiation of metronomic therapy. Events used in determining OS were deaths from any cause and for PFS included deaths from any cause, disease relapse, or disease progression. Kaplan-Meier statistical methods were employed for OS and PFS, and the log-rank test was used for comparisons. Cox proportional hazards regression modeling was used to determine which baseline parameters significantly affected the aforementioned endpoints. Logistic regression analysis was used to determine which factors were associated with the achievement of various response levels.
RESULTS
Patient Characteristics
Patient characteristics are listed in patients. More than 90% of patients had been exposed to novel agents such as bortezomib, thalidomide and lenalidomide, often in combination ( Table 1 ).
The incidence of cytopenia prior to the initiation of metronomic therapy was relatively high ( Table 2) . These cytopenias were due to extensive bone marrow infiltration of more than 70% in 40 out of 176 evaluable patients (23%). Cytotoxicity from chemotherapy, exhausted hematopoiesis and/or concurrent clinical myelodysplastic syndrome (MDS) was also considered as contributing to cytopenias. The most frequently occurring pre-existing non-hematological toxicities ≥ grade 2 were elevated creatinine > 1.3 mg/dL in 84 patients (45%) ; elevated liver enzymes (SGOT>41IU/L) in 76 (41%); and sensory neuropathy in 72 (39%) with 32 (17%) ( Table 2 and Suppl. Table 1 ). Thirty-seven (20%) patients had a hospitalization within 60 days before metronomic therapy initiation. The median number of cycles of metronomic therapy was 1 (1-5) with 47 (25%) having 2 or more.
Response and Survival
According to IMWG criteria (14) For the 71 patients with available GEP within 6 months prior to the initiation of metronomic therapy, OS was inferior in high-risk MM in both the GEP70 and GEP80 models (HR=2.42, P = 0.005 for GEP70 and HR=1.79, P = 0.07 for GEP80, univariate analysis) ( Figure 4A ). Proliferation Index as measured by GEP was an important correlate to OS in univariate analysis (HR = 2.00 P = 0.028). GEP70 risk designation also correlated with OS using the multivariate regression model (HR = 2.64, P = 0.003), along with CRP > 8.0 mg/dl (HR = 2.17, P = 0.013). Superior results in terms of OS were evident for the group of patients that were both low risk in the GEP70 model and had a normal baseline karyotype (P=0.0002) ( Figure 5A ). In the context of GEP data, no variable could achieve statistical significance for PFS regardless if CA were taken into account or not ( Figure 4B and 5B).
Of the 186 patients, 53 had PET examinations before and after metronomic therapy within two months from initiation and did not receive other intervening therapy.
Positive response in maximum standardized uptake FDG values (SUVmax) to values 3.9 or less tended to improve OS (HR=0.45, P = 0.081) and was unrelated to PFS. EMD diagnosed by PET-CT was present in 11 cases and showed a clear tendency towards statistical significance to affect adversely both OS and PFS (HR: 2.24, p=0.095 and HR:
2.27, p=0.051 for OS and PFS respectively) ( Table 4 ).Out of these 11 patients, 8
responded to metronomic treatment with a greater than 50% reduction in tumor size and suppression of SUV to baseline levels.
Toxicity
Patients were monitored for toxicity for two months after the initiation of metronomic therapy ( Table 5 and Suppl. Table 2 ). Most patients were treated in the outpatient setting (177/186, 95%). Secondary admissions due to any cause (regimenrelated toxicity or MM) occurred in 59 patients (32%), and secondary admissions thought to be due to regimen-related toxicity were estimated to have occurred in 37 patients (20%). Treatment related mortality (TRM) was only 1% (2/186).Grade 4 leukopenia, anemia, and thrombocytopenia due to metronomic therapy occurred in 108 (58%), 12 (6%), and 147 (79%) patients, respectively. Hematological toxicity was difficult to evaluate as the majority of the patients had preexisting cytopenia, as shown in Table 2 . Of interest, treatment-evolving clinically important cytopenia was largely restricted to those with pre-existing moderate to severe cytopenia. The detailed impact of metronomic therapy in hematological toxicity is depicted in Suppl. Table 3 and 
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Supplemental Figure 1
Dynamics of Thrombocytopenia before and after metronomic therapy.
None-Mild Thrombocytopenia Before Treatment, Moderate Thrombocytopenia Before Treatment, Severe
Thrombocytopenia Before Treatment, None-Mild Thrombocytopenia After Treatment, Moderate Thrombocytopenia After Treatment, Severe Thrombocytopenia After Treatment. Circularly arranged segments represent respective groups. Angular value of the segment, proportional to the size of the respective group. Ribbons with the respective color of the group before treatment ending (without touching) to the group after treatment proportionally to the percentage. Outer circularly arranged stacked bars representing the relative contribution of each group (before or after treatment) to the formation of another group (after or before treatment respectively).
